139 related articles for article (PubMed ID: 11937270)
1. Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy.
Azuma H; Yamada Y; Shibuya-Fujiwara N; Yamaguchi M; Murahashi H; Fujihara M; Sato N; Fukazawa K; Ikebuchi K; Ikeda H
Exp Hematol; 2002 Apr; 30(4):346-51. PubMed ID: 11937270
[TBL] [Abstract][Full Text] [Related]
2. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
3. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
Alvarnas JC; Linn YC; Hope EG; Negrin RS
Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
[TBL] [Abstract][Full Text] [Related]
4. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation.
Robinson KL; Ayello J; Hughes R; van de Ven C; Issitt L; Kurtzberg J; Cairo MS
Exp Hematol; 2002 Mar; 30(3):245-51. PubMed ID: 11882362
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
7. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
8. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
[TBL] [Abstract][Full Text] [Related]
9. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
10. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.
Meehan KR; Wu J; Webber SM; Barber A; Szczepiorkowski ZM; Sentman C
Cytotherapy; 2008; 10(1):30-7. PubMed ID: 18202972
[TBL] [Abstract][Full Text] [Related]
11. Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy.
Itoh H; Kakuta T; Kudo T; Sakonju I; Hohdatsu T; Ebina T; Takase K
J Vet Med Sci; 2003 Mar; 65(3):329-33. PubMed ID: 12679562
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood.
Condiotti R; Zakai YB; Barak V; Nagler A
Exp Hematol; 2001 Jan; 29(1):104-13. PubMed ID: 11164111
[TBL] [Abstract][Full Text] [Related]
13. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
Masuyama J; Murakami T; Iwamoto S; Fujita S
Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
[TBL] [Abstract][Full Text] [Related]
15. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients.
Sekine T; Shiraiwa H; Yamazaki T; Tobisu K; Kakizoe T
Biomed Pharmacother; 1993; 47(2-3):73-8. PubMed ID: 8218952
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
[TBL] [Abstract][Full Text] [Related]
17. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
18. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
[TBL] [Abstract][Full Text] [Related]
19. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
